
Investors target ADMA Biologics in new securities class action
Investors who purchased ADMA Biologics stock between August 9, 2024, and March 25, 2026, face a critical August 10 deadline to join a class action lawsuit. The litigation alleges the company misled shareholders by concealing related-party transactions and inflating sales figures through aggressive channel stuffing.






















